Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)

The goal of this clinical trial is to learn evaluate the safety and efficacy of the addition of radiation therapy to all tumour lesions, to first line medical treatment with alectinib in non-small cell lung cancer harbouring ALK-rearrangements. The main aims of the trial are to evaluate: * if the treatment combination is safe * if the treatment combination can inhibit progression Participants who have responded to 1st line alectinib will be treated with consolidation radiation therapy to all remaining tumour lesions while continuing on alectinib until disease progression, unacceptable toxic

Trial Details

NCT ID

NCT05724004

Phase

NA

Sponsor

Karolinska University Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• SBRT/SRS/radiation therapy

Locations (sample)

• Stockholm, Sweden|59.32938,18.06871

Key Eligibility Criteria

• Histological or cytological confirmed NSCLC:
• Stage IV NSCLC OR
• Stage III NSCLC not suitable for surgery or radiochemotherapy OR
• Recurrent NSCLC after previous surgery (not amendable for curative multimodal therapy)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →